Literature DB >> 3100543

Examination of blood-brain barrier permeability in dementia of the Alzheimer type with [68Ga]EDTA and positron emission tomography.

N L Schlageter, R E Carson, S I Rapoport.   

Abstract

Positron emission tomography with [68Ga]ethylenediaminetetraacetic acid ([68Ga]EDTA) was used to examine the integrity of the blood-brain barrier (BBB) in five patients with dementia of the Alzheimer type and in five healthy age-matched controls. Within a scanning time of 90 min, there was no evidence that measurable intravascular tracer entered the brain in either the dementia or the control group. An upper limit for the cerebrovascular permeability-surface area product of [68Ga]EDTA was estimated as 2 X 10(-6) s-1 in both groups. The results provide no evidence for breakdown of the BBB in patients with dementia of the Alzheimer type.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3100543     DOI: 10.1038/jcbfm.1987.1

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  30 in total

Review 1.  In vivo methods to study uptake of nanoparticles into the brain.

Authors:  Inge van Rooy; Serpil Cakir-Tascioglu; Wim E Hennink; Gert Storm; Raymond M Schiffelers; Enrico Mastrobattista
Journal:  Pharm Res       Date:  2010-10-07       Impact factor: 4.200

Review 2.  Brain fuel metabolism, aging, and Alzheimer's disease.

Authors:  Stephen Cunnane; Scott Nugent; Maggie Roy; Alexandre Courchesne-Loyer; Etienne Croteau; Sébastien Tremblay; Alex Castellano; Fabien Pifferi; Christian Bocti; Nancy Paquet; Hadi Begdouri; M'hamed Bentourkia; Eric Turcotte; Michèle Allard; Pascale Barberger-Gateau; Tamas Fulop; Stanley I Rapoport
Journal:  Nutrition       Date:  2010-10-29       Impact factor: 4.008

3.  Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future.

Authors:  Gene L Bowman; Joseph F Quinn
Journal:  Aging health       Date:  2008-02-01

4.  Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.

Authors:  D Wu; J Yang; W M Pardridge
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

Review 5.  Drug access to the central nervous system in Alzheimer's disease: preclinical and clinical insights.

Authors:  Dharmini C Mehta; Jennifer L Short; Sarah N Hilmer; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2014-10-16       Impact factor: 4.200

6.  Immunohistochemical localization of intracellular plasma proteins in the human central nervous system.

Authors:  H M Liu; J R Atack; S I Rapoport
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

7.  Measurement of human blood brain barrier integrity using 11C-inulin and positron emission tomography.

Authors:  T Hara; M Iio; T Tsukiyama; F Yokoi
Journal:  Eur J Nucl Med       Date:  1988

8.  Vector-mediated delivery of 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex.

Authors:  Y Saito; J Buciak; J Yang; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 9.  Can infections cause Alzheimer's disease?

Authors:  Francis Mawanda; Robert Wallace
Journal:  Epidemiol Rev       Date:  2013-01-24       Impact factor: 6.222

10.  Antibodies to choroid plexus in senile dementia of Alzheimer's type.

Authors:  J M Serot; M C Béné; B Gobert; D Christmann; B Leheup; G C Faure
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.